Hormone therapy not recommended for chronic disease prevention in menopausal women

Commentary on: Nelson HD, Walker M, Zakher B, et al.. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 2012;157:104–13. Context In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascular disease, dementia and osteoporosis. Clinical trial data dramatically changed clinical practice. The Heart and Estrogen/Progestin Replacement Study (HERS) examined conjugated equine oestrogen (CEE)+medroxyprogesterone acetate in women with coronary disease; hormone therapy did not decrease coronary events. Primary prevention was studied in the Women's Health Initiative (WHI) trial: E+P or E in women with hysterectomy. Both trials were terminated prematurely...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Pancreas and biliary tract, Epidemiologic studies, Drugs: cardiovascular system, Dementia, Stroke, Contraception, Drugs: obstetrics and gynaecology, Menopause (including HRT), Ischaemic heart disease, Venous thromboembolism, Memory disorders (psychiatry), Source Type: research